More than two years after paying $109 million to settle claims related to allegedly providing arthritis drug samples to doctors as kickbacks, pharma giant Sanofi has yet to sign a corporate integrity agreement with federal health regulators that was expected to follow that settlement.
The company said Friday, when asked about the status of that agreement, that it "expects to enter into a corporate integrity agreement with the Office of the Inspector General of the United States Department of Health and Human Services."
"Discussions with the U.S. government are ongoing to resolve the matter completely," Sanofi said.
Under such agreements, drug companies and medical providers say they will comply with various conditions after being accused of a False Claims Act violation in exchange for the OIG not seeking to bar them from participating in government-run insurance programs.
But even as that agreement remains in limbo, Sanofi is facing new allegations of kickbacks in a whistleblower lawsuit that claims the company and its then CEO paid out tens of millions of dollars in kickbacks to induce doctors, hospitals and pharmacy chains to prescribe and buy diabetes drugs.
Read MoreSuit claims Sanofi 'kickback' scheme
Sanofi also was sued in Manhattan federal court on Thursday night in a shareholder class-action suit, which mentions both the whistleblower's claims, the recent ouster of Sanofi CEO Christopher Viehbacher and the company's announcement in October that it was investigating "anonymous allegations" of improper payments to health-care professionals in the Middle East and East Africa in connection with the sale of pharmaceutical products.
Sanofi's 2012 settlement with the Justice Department related to samples of the arthritis drug Hyalgan contains an ominous warning to the company of possible further sanctions by the government even without a corporate integrity agreement being in place if authorities determine the company isn't behaving.